Mumbai: India's pharmaceutical giant Sun Pharma delivered stronger-than-expected quarterly earnings, underlining the resilience of its domestic operations even as competitive pressures weighed on its US generic medicines business.
For the quarter ended June 2026, the company reported a consolidated net profit of ₹2,895 crore, up 27% from ₹2,279 crore recorded in the same period last year. Revenue from operations climbed 10.5% to ₹15,300 crore, reflecting healthy demand across key therapeutic segments in India.
The Indian market remained the company's biggest growth engine. Domestic pharmaceutical sales increased 16% year-on-year to ₹5,475 crore, accounting for 36.1% of consolidated sales. Sun Pharma also strengthened its leadership position in the Indian pharmaceutical market, with market share rising to 8.5%, supported by the launch of five new products and continued dominance across multiple medical specialties.
While the company continued to expand in India, its US business faced headwinds. Formulation sales in the United States declined 10% to $427 million, primarily due to intense competition and pricing pressure in generic medicines. However, Sun Pharma's higher-margin specialty and innovative medicines business helped cushion the impact, with specialty sales increasing 13% to $351 million.
The company also reported stable international performance beyond the US. Sales in emerging markets rose 4% to $311 million, while other global markets contributed $218 million. External sales from the Active Pharmaceutical Ingredients (API) business grew 10.5% to ₹597 crore, reflecting sustained demand from domestic and international customers.
Research and innovation remained a strategic priority. Sun Pharma invested ₹826 crore in research and development during the quarter, representing 5.4% of total sales. Its clinical pipeline currently includes five investigational medicines, while the company holds 558 approved ANDAs in the United States with 119 additional applications awaiting regulatory clearance.
Despite the encouraging financial results, the company's shares ended the trading session 0.53% lower at ₹1,990.50, suggesting investors remained cautious amid broader market conditions and concerns over continued weakness in the US generics segment.
Long-term investors, however, have seen substantial wealth creation. Sun Pharma shares have generated returns of approximately 157% over the past five years, highlighting the company's sustained growth trajectory and leadership in India's pharmaceutical industry.
